Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease
Identifieur interne : 001523 ( Main/Exploration ); précédent : 001522; suivant : 001524Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease
Auteurs : Chen [États-Unis] ; Swope [États-Unis]Source :
- The Journal of Clinical Pharmacology [ 0091-2700 ] ; 2005-08.
English descriptors
Abstract
Rasagiline is a novel second‐generation propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO‐B). For the management of Parkinson disease (PD), rasagiline is efficacious across the span of PD stages ranging from monotherapy in early disease to adjunctive treatment in patients with advancing disease and motor fluctuations. Rasagiline completely and selectively inhibits MAO‐B with a potency 5 to 10 times greater than selegiline. Unlike the prototype propargylamine selegiline, which is metabolized to amphetamine derivatives, rasagiline is biotransformed to aminoindan, a non‐amphetamine compound. Rasagiline is well tolerated with infrequent cardiovascular or psychiatric side effects, and at the recommended therapeutic dose of up to 1 mg once daily, tyramine restriction is unnecessary. In addition to MAO‐B inhibition, the propargylamine chain also confers dose‐related antioxidant and antiapoptotic effects, which have been associated with neuroprotection in multiple experimental models. Thus, in addition to symptomatic benefits, rasagiline offers the promise of clinically relevant neuroprotection.
Url:
DOI: 10.1177/0091270005277935
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease</title><author><name sortKey="Chen" sort="Chen" uniqKey="Chen" last="Chen">Chen</name></author><author><name sortKey="Swope" sort="Swope" uniqKey="Swope" last="Swope">Swope</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:64D82D2EC2B4AF6C605F6D303DAEB166603E4119</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1177/0091270005277935</idno><idno type="url">https://api.istex.fr/document/64D82D2EC2B4AF6C605F6D303DAEB166603E4119/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000585</idno><idno type="wicri:Area/Main/Curation">000510</idno><idno type="wicri:Area/Main/Exploration">001523</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease</title><author><name sortKey="Chen" sort="Chen" uniqKey="Chen" last="Chen">Chen</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Movement Disorders Center, Loma Linda University, Loma Linda</wicri:cityArea></affiliation><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Pharmacy Practice, Western University of Health Sciences, Pomona</wicri:cityArea></affiliation></author><author><name sortKey="Swope" sort="Swope" uniqKey="Swope" last="Swope">Swope</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Movement Disorders Center, Loma Linda University, Loma Linda</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">The Journal of Clinical Pharmacology</title><idno type="ISSN">0091-2700</idno><idno type="eISSN">1552-4604</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2005-08">2005-08</date><biblScope unit="volume">45</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="878">878</biblScope><biblScope unit="page" to="894">894</biblScope></imprint><idno type="ISSN">0091-2700</idno></series><idno type="istex">64D82D2EC2B4AF6C605F6D303DAEB166603E4119</idno><idno type="DOI">10.1177/0091270005277935</idno><idno type="ArticleID">JCPH5875</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0091-2700</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Monoamine oxidase</term><term>Parkinson disease</term><term>neuroprotection</term><term>propargylamines</term><term>rasagiline</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Rasagiline is a novel second‐generation propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO‐B). For the management of Parkinson disease (PD), rasagiline is efficacious across the span of PD stages ranging from monotherapy in early disease to adjunctive treatment in patients with advancing disease and motor fluctuations. Rasagiline completely and selectively inhibits MAO‐B with a potency 5 to 10 times greater than selegiline. Unlike the prototype propargylamine selegiline, which is metabolized to amphetamine derivatives, rasagiline is biotransformed to aminoindan, a non‐amphetamine compound. Rasagiline is well tolerated with infrequent cardiovascular or psychiatric side effects, and at the recommended therapeutic dose of up to 1 mg once daily, tyramine restriction is unnecessary. In addition to MAO‐B inhibition, the propargylamine chain also confers dose‐related antioxidant and antiapoptotic effects, which have been associated with neuroprotection in multiple experimental models. Thus, in addition to symptomatic benefits, rasagiline offers the promise of clinically relevant neuroprotection.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Chen" sort="Chen" uniqKey="Chen" last="Chen">Chen</name></region><name sortKey="Chen" sort="Chen" uniqKey="Chen" last="Chen">Chen</name><name sortKey="Swope" sort="Swope" uniqKey="Swope" last="Swope">Swope</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001523 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001523 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:64D82D2EC2B4AF6C605F6D303DAEB166603E4119
|texte= Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease
}}
| This area was generated with Dilib version V0.6.23. |  |